Nichi-Iko Slashes Profitability Guidance As Supply Issues Drag On
‘Delay In Shipments Has Led To Generic Supply Problems In Japan’
Nichi-Iko has been forced to cut dramatically its core operating profit guidance for its 2022 financial year, as it continues to deal with the fallout of its previously deficient Namerikawa manufacturing facility in the Toyama prefecture.
You may also be interested in...
Sawai Maintains Strong Domestic Performance, Continues To Flounder In US
Sawai’s Q2 results mirrored those of Q1, with a strong performance in Japan but a weak one in the US. The firm is continuing to focus on establishing new production facilities in both territories.
Nippon Chemiphar’s Generics Business Continues To Recover
Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.
Sawai Cites Broader Supply Issue As It Plots Construction Of A New Facility
Japan’s Sawai was cautioned by one analyst earlier this year that it lacked sufficient excess production capacity to handle the sharp expansion in demand for its products. Now the company has announced plans to build a new solid dosage form facility.